A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication
NCT01317810 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2015-09-02
Summary
The purpose of this study is to track changes in overactive bladder (OAB) medical regimen and/or OAB medication dosage requirements.
Conditions
- Overactive Bladder (OAB)
Sponsors & Collaborators
- collaborator INDUSTRY
-
Astellas Pharma Inc
lead INDUSTRY
Principal Investigators
-
Use Central Contact · Astellas Pharma Global Development, Inc.
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.
NCT00645281 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
NCT02216214 ·Status: COMPLETED ·Phase: PHASE4
-
A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)
NCT02386072 ·Status: COMPLETED
-
A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
NCT03572231 ·Status: COMPLETED
-
Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder
NCT00366002 ·Status: COMPLETED ·Phase: PHASE4
-
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
NCT00409539 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of the Overactive Bladder Syndrome: A Delphi Study
NCT04300400 ·Status: COMPLETED
-
Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB)
NCT04545580 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Caffeine Reduction and Anticholinergic Medications for Treatment of Overactive Bladder
NCT00780832 ·Status: TERMINATED ·Phase: NA
-
A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice
NCT02320773 ·Status: COMPLETED
-
A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder
NCT00966004 ·Status: COMPLETED ·Phase: PHASE3
-
Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients
NCT00730535 ·Status: COMPLETED ·Phase: PHASE4
-
A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden
NCT03903094 ·Status: COMPLETED
-
Reproducibility Study of Over Active Bladder Symptom Score [OABSS]
NCT00901251 ·Status: COMPLETED
-
Developing a Simple Test to Diagnose Overactive Bladder
NCT05572918 ·Status: UNKNOWN
-
Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence
NCT01157377 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of YM178 in Patients With Symptomatic Overactive Bladder
NCT00527033 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity
NCT00335660 ·Status: TERMINATED ·Phase: PHASE2
-
Oxybutynin and Omega-3 for OAB (Overactive Bladder)
NCT02070042 ·Status: TERMINATED ·Phase: NA
-
Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder
NCT00171184 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00689104 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
NCT03602508 ·Status: COMPLETED
-
Reproducibility Study of OABSS and Its Response to Treatment
NCT02667470 ·Status: COMPLETED ·Phase: PHASE4
-
Assessing the OAB-8 Questionnaire as a Tool to Measure Treatment Outcome
NCT00313924 ·Status: UNKNOWN ·Phase: PHASE4
-
SVT-40776 in Patients Suffering From Overactive Bladder Syndrome
NCT00507169 ·Status: COMPLETED ·Phase: PHASE2